Early anti-VEGF treatment of diabetic reti nopathy yields no benefit to visual acuity

Niaid.nih.gov

Click here to subscribe to Niaid.nih.gov

1 year ago

Html
Text

Having trouble viewing this email? View it as a Web page.

You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).

Early anti-VEGF treatment of diabetic retinopathy yields no benefit to visual acuity 02/07/2023 11:00 AM EST
Findings from NIH-supported clinical trial help guide management of diabetic eye disease.

Update Your E-mail Address | Add Subscriptions | Unsubscribe All

If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view ourFrequently Asked Questions page, our Health Information page, or Search our website.

This service is provided to you by the National Institutes of Health.
NIHTurning Discovery Into Health

This email was sent to newsletter@newslettercollector.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) 9000 Rockville Pike Bethesda MD 20892 301-496-4000 / TTY 301-402-9612

Share on

Other newsletters from Niaid.nih.gov

Spotlight on Herbs and Other Botanicals Niaid.nih.gov
an hour ago
Find a plan for 2025! There is still time to enroll Niaid.nih.gov
5 hours ago
HRSA Supports Rural Health Care Niaid.nih.gov
Last Friday at 18:07

More newsletters from Niaid.nih.gov

Early anti-VEGF treatment of diabetic reti nopathy yields no benefit to visual acuity

Share on

Other newsletters from Niaid.nih.gov

Related newsletters